news
Ipsen agrees new oncology licensing deal
The agreement relates to an innovative therapeutic for the most common paediatric brain cancer, where outside the US, there is no approved targeted treatment for certain patients.
List view / Grid view
Ipsen
article
Uncovering the potential of ADCs to target tumours
Antibody drug conjugates (ADCs) are set to play a pivotal role in the future of oncology, thanks to their potential to offer targeted treatments with a lower risk of side effects. Here, Mary Jane Hinrichs, Senior Vice President of Early Development at Ipsen, examines how ADCs could transform treatment options…
news
Could small molecule medicine treat rare liver disease?
A novel PPAR alpha/delta agonist “could provide an important new therapeutic option for long-term treatment [of primary biliary cholangitis (PBC)].
news
£277m investment to advance UK life sciences manufacturing
Four UK life sciences companies are set to benefit from a £277m investment in the first tranche of Life Sciences Innovative Manufacturing Fund (LSIMF) grants.
news
Onivyde® improves survival in Phase III pancreatic cancer trial
Onivyde® (irinotecan liposome injection) treatment regimen significantly improved survival in a Phase III trial compared to nab-paclitaxel plus gemcitabine.
news
EC approves Cabometyx® and Opdivo® combination for advanced renal cell carcinoma
The combination was approved on Phase III trial results which show it doubled progression-free survival and reduced risk of death by 40 percent, compared to standard of care.
news
MHRA approves cerebral palsy spasticity drug to treat children
Dysport®, a therapy for spasticity in cerebral palsy patients has been granted a license update to treat children aged two years and older.
news
Clinical trial reporting is improved by professional medical writers
A new systematic review has shown that the speed and quality of clinical trial reports are improved by professional medical writers.
news
NICE recommends cabozantinib for advanced renal cell cancer
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
news
Scotland approves Ipsen’s cabozantinib to treat kidney cancer
The SMC endorses routine prescribing across NHS Scotland of Ipsen’s cabozantinib, offering a new therapy option to help battle kidney cancer.
news
Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
news
EC approves Ipsen’s cabometyx to treat advanced RCC following VEGF-targeted therapy
16 September 2016 | By Niamh Louise Marriott,
The European Commission has approved Ibsen’s cabometyx (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx (cabozantinib) demonstrated significant clinical benefits across all three efficacy endpoints (OS, PFS, ORR) in a phase 3…
news
Ipsen’s kidney cancer drug receives positive CHMP and ‘Promising Innovative Medicine’ status
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Ipsen announced that CHMP & EMA have provided a positive opinion for Cabometyx for the treatment of advanced renal cell carcinoma (RCC) in adults...
news
Ipsen announces additional Phase III study results for Dysport
23 October 2015 | By Victoria White
The Phase III study evaluated the investigational use of Dysport for the treatment of spastic equinus foot, a condition associated with cerebral palsy in children aged 2-17...
news
Positive top-line results for Phase 3 telotristat etiprate study
3 August 2015 | By Victoria White
A Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome...
